$RGBP
Regen BioPharma Inc Stock $rgbp

$rgbp Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000160706223000028 Filed on January 19, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2021 Q4
Revenue	$31.64K	$31.64K	$59.07K
YoY Change	-45.79%	-46.44%	115.43%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$101.5K	$427.4K	$49.79K
YoY Change	43.91%	758.45%	11.19%
% of Gross Profit
Research & Development	$36.45K	$95.51K	$115.7K
YoY Change	-43.38%	-17.44%	10138.05%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$36.45K	$95.51K	$165.5K
YoY Change	-72.97%	-42.28%	260.54%
Operating Profit	-$78.84K	-$463.9K	-$106.4K
YoY Change	3.07%	335.88%
Interest Expense	$12.09K	$17.36K	$2.784M
YoY Change	-100.02%	-99.38%	65.22%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$62.70K
YoY Change	-100.0%	-100.0%
Pretax Income	-$54.98K	$1.636M	$2.645M
YoY Change	-99.92%	-38.16%	58.73%
Income Tax
% Of Pretax Income
Net Earnings	-$54.98K	$1.636M	$2.645M
YoY Change	-99.92%	-38.16%	58.73%
Net Earnings / Revenue	-173.76%	5169.82%	4477.7%
Basic Earnings Per Share		$0.45
Diluted Earnings Per Share	-$0.03	$0.43	$581.30
COMMON SHARES
Basic Shares Outstanding	5.048B shares	5.032B shares	4.507B shares
Diluted Shares Outstanding		3.361M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$87.70K	$40.74K	$353.5K
YoY Change	-62.63%	-88.47%
Cash & Equivalents	$87.70K	$40.74K	$353.5K
Short-Term Investments
Other Short-Term Assets	$17.23K	$19.09K	$41.29K
YoY Change	-50.17%	-53.77%	206350.0%
Inventory
Prepaid Expenses	$7.233K	$14.09K
Receivables	$79.12K	$131.7K	$240.6K
Other Receivables	$0.00	$0.00	$5.760K
Total Short-Term Assets	$184.1K	$191.5K	$641.2K
YoY Change	-66.12%	-70.13%	390.82%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$222.6K	$222.6K	$94.08K
YoY Change	153.85%	136.59%	371.11%
Other Assets
YoY Change
Total Long-Term Assets	$222.6K	$222.6K	$94.08K
YoY Change	153.85%	136.59%	371.11%
TOTAL ASSETS
Total Short-Term Assets	$184.1K	$191.5K	$641.2K
Total Long-Term Assets	$222.6K	$222.6K	$94.08K
Total Assets	$406.6K	$414.1K	$735.2K
YoY Change	-35.54%	-43.68%	388.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$34.05K	$31.04K	$32.29K
YoY Change	-18.22%	-3.87%	-71.64%
Accrued Expenses	$1.616M	$1.614M	$1.974M
YoY Change	-18.28%	-18.26%	-9.38%
Deferred Revenue
YoY Change
Short-Term Debt	$101.7K	$1.710K	$1.453M
YoY Change	8169.11%	-99.88%	2201.01%
Long-Term Debt Due	$509.9K	$509.9K	$1.272M
YoY Change	-82.99%	-59.92%	-49.58%
Total Short-Term Liabilities	$5.336M	$5.299M	$10.49M
YoY Change	-93.1%	-49.49%	83.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.336M	$5.299M	$10.49M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$5.336M	$5.299M	$10.49M
YoY Change	-93.1%	-49.49%	83.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.32M	-$19.27M
YoY Change
Common Stock	$339.00	$504.8K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.930M	-$4.885M	-$9.756M
YoY Change
Total Liabilities & Shareholders Equity	$406.6K	$414.1K	$735.2K
YoY Change	-35.54%	-43.68%	388.21%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2021 Q4
OPERATING ACTIVITIES
Net Income	-$54.98K	$1.636M	$2.645M
YoY Change	-99.92%	-38.16%	58.73%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$53.04K	-$10.46K	-$279.1K
YoY Change	-55.36%	-96.25%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change
Cash From Investing Activities		$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	100.0K	$0.00	-94.54K
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-53.04K	-$10.46K	-279.1K
Cash From Investing Activities		$0.00	0.000
Cash From Financing Activities	100.0K	$0.00	-94.54K
Net Change In Cash	46.96K	-$10.46K	-373.7K
YoY Change	-139.53%	-97.2%
FREE CASH FLOW
Cash From Operating Activities	-$53.04K	-$10.46K	-$279.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Cash Cash	40741	usd
CY2022Q3	us-gaap	Cash Cash	51204	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	131698	usd
CY2022Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001589150
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	254273	usd
CY2022Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	0	usd
CY2022Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2022Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5048430270	shares
CY2022Q4	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2022Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q4	dei	Document Quarterly Report DocumentQuarterlyReport	false
CY2022Q4	dei	Document Type DocumentType	10-Q
CY2022Q4	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q4	dei	Entity File Number EntityFileNumber	333-191725
CY2022Q4	dei	Entity Registrant Name EntityRegistrantName	REGEN BIOPHARMA, INC.
CY2022Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5192997
CY2022Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	4700 Spring Street
CY2022Q4	dei	Entity Address Address Line2 EntityAddressAddressLine2	St 304
CY2022Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	La Mesa
CY2022Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91942
CY2022Q4	dei	City Area Code CityAreaCode	619
CY2022Q4	dei	Local Phone Number LocalPhoneNumber	722-5505
CY2022Q3	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	0	usd
CY2022Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	0	usd
CY2022Q3	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	0	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	14089	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	20945	usd
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	5000	usd
CY2022Q3	us-gaap	Prepaid Rent PrepaidRent	10000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	191528	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	336422	usd
CY2022Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	0	usd
CY2022Q4	RGBP	Investment Securities Related Party InvestmentSecuritiesRelatedParty	222580	usd
CY2022Q3	RGBP	Investment Securities Related Party InvestmentSecuritiesRelatedParty	222580	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	222580	usd
CY2022Q3	us-gaap	Other Assets OtherAssets	222580	usd
CY2022Q4	us-gaap	Assets Assets	414108	usd
CY2022Q3	us-gaap	Assets Assets	559002	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	31039	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	28799	usd
CY2022Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	710	usd
CY2022Q3	us-gaap	Notes And Loans Payable NotesAndLoansPayable	710	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4241	usd
CY2022Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4241	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	301363	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	689785	usd
CY2022Q4	RGBP	Accrued Rent AccruedRent	0	usd
CY2022Q3	RGBP	Accrued Rent AccruedRent	0	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1266679	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1266679	usd
CY2022Q4	RGBP	Other Accrued Expenses OtherAccruedExpenses	41423	usd
CY2022Q3	RGBP	Other Accrued Expenses OtherAccruedExpenses	41423	usd
CY2022Q4	us-gaap	Bank Overdrafts BankOverdrafts	1000	usd
CY2022Q3	us-gaap	Bank Overdrafts BankOverdrafts	1000	usd
CY2022Q4	RGBP	Due To Investor DueToInvestor	20000	usd
CY2022Q3	RGBP	Due To Investor DueToInvestor	20000	usd
CY2022Q4	RGBP	Unearned Income UnearnedIncome	1686650	usd
CY2022Q3	RGBP	Unearned Income UnearnedIncome	1718290	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1435949	usd
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	3551793	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	499880	usd
CY2022Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1262340	usd
CY2022Q4	RGBP	Convertible Notes Payable Related Parties Less Unamortized Discount ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount	10000	usd
CY2022Q3	RGBP	Convertible Notes Payable Related Parties Less Unamortized Discount ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount	10000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5298935	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8595061	usd
CY2022Q4	RGBP	Convertible Notes Payable Related Parties Less Unamortized Discount Noncurrent ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNoncurrent	0	usd
CY2022Q3	RGBP	Convertible Notes Payable Related Parties Less Unamortized Discount Noncurrent ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNoncurrent	0	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5298935	usd
CY2022Q3	us-gaap	Liabilities Liabilities	8595061	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5800000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5031517324	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50848430270	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	504843	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	503150	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	13078374	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11581499	usd
CY2022Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	736326	usd
CY2022Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	736326	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19269640	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20905369	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4884826	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8036059	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	414108	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	559002	usd
CY2022Q4	us-gaap	Revenues Revenues	31640	usd
CY2021Q4	us-gaap	Revenues Revenues	31640	usd
CY2022Q4	RGBP	Revenues Related Party RevenuesRelatedParty	27425	usd
CY2021Q4	RGBP	Revenues Related Party RevenuesRelatedParty	27425	usd
CY2022Q4	RGBP	Total Revenues TotalRevenues	59065	usd
CY2021Q4	RGBP	Total Revenues TotalRevenues	59065	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	95513	usd
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35418	usd
CY2022Q4	RGBP	Research And Development Related Party ResearchAndDevelopmentRelatedParty	0	usd
CY2021Q4	RGBP	Research And Development Related Party ResearchAndDevelopmentRelatedParty	80275	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8738	usd
CY2021Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6658	usd
CY2022Q4	us-gaap	Professional Fees ProfessionalFees	403680	usd
CY2021Q4	us-gaap	Professional Fees ProfessionalFees	38136	usd
CY2022Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	15000	usd
CY2021Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	5000	usd
CY2022Q4	us-gaap	Costs And Expenses CostsAndExpenses	522931	usd
CY2021Q4	us-gaap	Costs And Expenses CostsAndExpenses	165487	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-463867	usd
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-106422	usd
CY2022Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	usd
CY2021Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	135	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	17359	usd
CY2021Q4	us-gaap	Interest Expense InterestExpense	35010	usd
CY2022Q4	RGBP	Interest Expense Attributable To Amortization Of Discount InterestExpenseAttributableToAmortizationOfDiscount	0	usd
CY2021Q4	RGBP	Interest Expense Attributable To Amortization Of Discount InterestExpenseAttributableToAmortizationOfDiscount	-22451	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	-0	usd
CY2021Q4	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	-0	usd
CY2022Q4	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	0	usd
CY2021Q4	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	-123891	usd
CY2022Q4	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	usd
CY2021Q4	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	usd
CY2022Q4	RGBP	Gain Loss On Derecognition Of Accounts Payable GainLossOnDerecognitionOfAccountsPayable	0	usd
CY2021Q4	RGBP	Gain Loss On Derecognition Of Accounts Payable GainLossOnDerecognitionOfAccountsPayable	62700	usd
CY2022Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2115806	usd
CY2021Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2964939	usd
CY2022Q4	RGBP	Financing Fees FinancingFees	0	usd
CY2021Q4	RGBP	Financing Fees FinancingFees	0	usd
CY2022Q4	RGBP	Legal Settlement LegalSettlement	0	usd
CY2021Q4	RGBP	Legal Settlement LegalSettlement	0	usd
CY2022Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1150	usd
CY2021Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-95019	usd
CY2022Q4	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2099596	usd
CY2021Q4	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2751403	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	1635730	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	2644980	usd
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1448439	usd
CY2021Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2391062	usd
CY2022Q4	RGBP	Basic And Fully Diluted Earnings Loss Per Share BasicAndFullyDilutedEarningsLossPerShare	0.0003
CY2021Q4	RGBP	Basic And Fully Diluted Earnings Loss Per Share BasicAndFullyDilutedEarningsLossPerShare	0.001
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5040810152	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4506953931	shares
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-13485877	usd
CY2021Q4	RGBP	Shares Issued For Debt Amount SharesIssuedForDebtAmount	100000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value SharesIssuedForInterestValue	26662	usd
CY2021Q4	RGBP	Shares Issued For Debt1 Amount SharesIssuedForDebt1Amount	100000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value1 SharesIssuedForInterestValue1	38837	usd
CY2021Q4	RGBP	Shares Issued For Debt2 Amount SharesIssuedForDebt2Amount	50000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value2 SharesIssuedForInterestValue2	19603	usd
CY2021Q4	RGBP	Shares Issued For Debt3 Amount SharesIssuedForDebt3Amount	50000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value3 SharesIssuedForInterestValue3	18575	usd
CY2021Q4	RGBP	Shares Issued For Interest Value4 SharesIssuedForInterestValue4	75000	usd
CY2021Q4	RGBP	Shares Issued For Debt4 Amount SharesIssuedForDebt4Amount	32075	usd
CY2021Q4	RGBP	Shares Issued For Interest Value5 SharesIssuedForInterestValue5	25000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value6 SharesIssuedForInterestValue6	10356	usd
CY2021Q4	RGBP	Shares Issued For Debt5 Amount SharesIssuedForDebt5Amount	25000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value7 SharesIssuedForInterestValue7	8883	usd
CY2021Q4	RGBP	Shares Issued For Debt6 Amount SharesIssuedForDebt6Amount	50000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value8 SharesIssuedForInterestValue8	23369	usd
CY2021Q4	RGBP	Shares Issued For Debt7 Amount SharesIssuedForDebt7Amount	100000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value9 SharesIssuedForInterestValue9	39808	usd
CY2021Q4	RGBP	Shares Issued For Debt8 Amount SharesIssuedForDebt8Amount	40000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value10 SharesIssuedForInterestValue10	14192	usd
CY2021Q4	RGBP	Shares Issued For Debt9 Amount SharesIssuedForDebt9Amount	50000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value11 SharesIssuedForInterestValue11	19012	usd
CY2021Q4	RGBP	Shares Issued For Debt10 Amount SharesIssuedForDebt10Amount	10964	usd
CY2021Q4	RGBP	Shares Issued For Debt11 Amount SharesIssuedForDebt11Amount	25000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value12 SharesIssuedForInterestValue12	11527	usd
CY2021Q4	RGBP	Shares Issued For Debt12 Amount SharesIssuedForDebt12Amount	60000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value13 SharesIssuedForInterestValue13	25440	usd
CY2021Q4	RGBP	Shares Issued For Debt13 Amount SharesIssuedForDebt13Amount	25000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value14 SharesIssuedForInterestValue14	10625	usd
CY2021Q4	us-gaap	Profit Loss ProfitLoss	2644980	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9755969	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-8036059	usd
CY2022Q4	RGBP	Preferred Shares Issued For Nonemployee Services PreferredSharesIssuedForNonemployeeServices	300000	usd
CY2022Q4	RGBP	Preferred Shares Issued For Debt PreferredSharesIssuedForDebt	761500	usd
CY2022Q4	RGBP	Preferred Shares Issued For Interest PreferredSharesIssuedForInterest	380262	usd
CY2022Q4	RGBP	Common Shares Issued For Interest CommonSharesIssuedForInterest	25369	usd
CY2022Q4	RGBP	Preferred Shares Issued For Nonemployee Services1 PreferredSharesIssuedForNonemployeeServices1	48372	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	1635730	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4884826	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	1635730	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	2644980	usd
CY2022Q4	RGBP	Common Stock Issued For Expenses CommonStockIssuedForExpenses	-0	usd
CY2022Q4	RGBP	Preferred Stock Issued As Compensation PreferredStockIssuedAsCompensation	-348372	usd
CY2022Q4	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2021Q4	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	22451	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2240	usd
CY2021Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-59210	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-122575	usd
CY2021Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	27425	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	17359	usd
CY2021Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6036	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-11856	usd
CY2021Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-6856	usd
CY2022Q4	RGBP	Increase Decrease In Contributed Capital IncreaseDecreaseInContributedCapital	0	usd
CY2022Q4	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-2115806	usd
CY2021Q4	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-2964939	usd
CY2022Q4	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-31640	usd
CY2021Q4	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-31640	usd
CY2022Q4	RGBP	Increase Decrease In Penalties IncreaseDecreaseInPenalties	0	usd
CY2022Q4	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	-0	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-0	usd
CY2021Q4	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	135	usd
CY2022Q4	RGBP	Securities Accepted As Compensation SecuritiesAcceptedAsCompensation	-0	usd
CY2022Q4	RGBP	Gain Loss On Forgiveness Of Debt GainLossOnForgivenessOfDebt	1150	usd
CY2022Q4	RGBP	Increase Decrease In Loss On Sale Of Investment Securities IncreaseDecreaseInLossOnSaleOfInvestmentSecurities	-0	usd
CY2022Q4	RGBP	Unrealized Lossgain On Investment Securities UnrealizedLossgainOnInvestmentSecurities	-0	usd
CY2021Q4	RGBP	Unrealized Lossgain On Investment Securities UnrealizedLossgainOnInvestmentSecurities	-123891	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10463	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-279135	usd
CY2022Q4	RGBP	Increasedecrease In Sale Of Investment Securities IncreasedecreaseInSaleOfInvestmentSecurities	0	usd
CY2021Q4	RGBP	Increasedecrease In Sale Of Investment Securities IncreasedecreaseInSaleOfInvestmentSecurities	0	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022Q4	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	0	usd
CY2021Q4	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	0	usd
CY2021Q4	RGBP	Increase Decrease In Convertible Notes Payable IncreaseDecreaseInConvertibleNotesPayable	-94535	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-94535	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10463	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-373670	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51204	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	727162	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40741	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	353492	usd
CY2022Q4	RGBP	Common Shares Issued For Debt CommonSharesIssuedForDebt	0	usd
CY2021Q4	RGBP	Common Shares Issued For Debt CommonSharesIssuedForDebt	710964	usd
CY2022Q4	RGBP	Preferred Share Issued For Debt PreferredShareIssuedForDebt	761500	usd
CY2021Q4	RGBP	Preferred Share Issued For Debt PreferredShareIssuedForDebt	75000	usd
CY2022Q4	us-gaap	Interest Paid InterestPaid	0	usd
CY2021Q4	us-gaap	Interest Paid InterestPaid	28973	usd
CY2022Q4	RGBP	Common Shares Issued For Interests CommonSharesIssuedForInterests	25369	usd
CY2021Q4	RGBP	Common Shares Issued For Interests CommonSharesIssuedForInterests	264970	usd
CY2022Q4	RGBP	Preferred Shares Issued For Interests PreferredSharesIssuedForInterests	380262	usd
CY2021Q4	RGBP	Preferred Shares Issued For Interests PreferredSharesIssuedForInterests	33994	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0389	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	8.8214	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1	pure
CY2022Q4	us-gaap	Advertising Expense AdvertisingExpense	0	usd
	RGBP	Net Income Loss Since Inception NetIncomeLossSinceInception	19269840	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	710	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5800000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares

Files In Submission

Name	View Source	Status
0001607062-23-000028-index-headers.html	Edgar Link	pending
0001607062-23-000028-index.html	Edgar Link	pending
0001607062-23-000028.txt	Edgar Link	pending
0001607062-23-000028-xbrl.zip	Edgar Link	pending
ex10_1.htm	Edgar Link	pending
ex10_2.htm	Edgar Link	pending
ex10_3.htm	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
rgbp-20221231.xsd	Edgar Link	pending
rgbp123122form10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rgbp-20221231_def.xml	Edgar Link	unprocessable
rgbp-20221231_pre.xml	Edgar Link	unprocessable
rgbp-20221231_lab.xml	Edgar Link	unprocessable
rgbp-20221231_cal.xml	Edgar Link	unprocessable
rgbp123122form10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGBP
Regen BioPharma Inc Stock $rgbp

2023 Q1 Form 10-Q Financial Statement

#000160706223000028 Filed on January 19, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGBP Regen BioPharma Inc Stock $rgbp

2023 Q1 Form 10-Q Financial Statement

#000160706223000028 Filed on January 19, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGBP
Regen BioPharma Inc Stock $rgbp